Скачать или смотреть Quince Therapeutics 2025 Investor Day

Watch Quince's 2025 Investor Day where we shared the latest clinical development and corporate updates including:

· Quince Overview – Learn about the company’s pioneering Autologous Intracellular Drug Encapsulation (AIDE) technology designed to chronically deliver corticosteroids without toxicity and the potential to transform treatment paradigms across multiple rare disease indications where corticosteroids are the standard of care.

· Technology Deep Dive – A look at the company’s proprietary eDSP System, which is a unique drug/device combination that uses an automated process designed to encapsulate dexamethasone sodium phosphate (eDSP) in a patient’s own red blood cells to allow for the chronic, monthly administration of corticosteroids without toxicity.

· Lead Indication: Ataxia-Telangiectasia (A-T) – Insights into this devastating pediatric rare disease, encouraging prior ATTeST study results, and the company's fully enrolled pivotal Phase 3 NEAT clinical trial with topline results expected in the first quarter of 2026.

· Mechanism of Action – Learn about multiple synergistic mechanisms of action that lead to eDSP’s efficacy and disease modifying activity while mitigating corticosteroid toxicity, and how transcriptomic profiling reveals novel insights and potential biomarkers in A-T.

· Regulatory Overview – Discussion of the company’s Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration, orphan drug and Fast Track designations, and the anticipated regulatory approval pathway for eDSP, assuming positive NEAT study results.

· Commercial Development – Insights into the company’s attractive commercial opportunity and launch preparedness planning for eDSP, including details of its recently announced strategic relationship with Option Care Health.

· Driving Value Creation – A look at the company’s strong competitive positioning, significant opportunity to quickly expand its development pipeline into additional high-value, rare disease indications like Duchenne muscular dystrophy, and its existing cash runway which provides funding through topline results and into the second quarter of 2026.

The session concludes with a live Q&A with Quince's leadership team.